C. Eschbach

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

Martin Reck, R. Kaiser, C. Eschbach et al. · Annals of Oncology · 2011 · 149 citations · Full text

Medicine, Clinical Trials, Bronchial Neoplasm +6

Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study

Kenneth J. O’Byrne, Igor Bondarenko, Carlos Barrios et al. · Journal of Clinical Oncology · 2009 · 92 citations

Malignant Disease, Medicine, Kras Mutation +13

A longitudinal communication approach in advanced lung cancer: A qualitative study of patients’, relatives’ and staff's perspectives

Matthias Villalobos, K. Coulibaly, Katja Krug et al. · European Journal of Cancer Care · 2017 · 30 citations

Family Medicine, Longitudinal Communication Approach, Communication +20

Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED- SCLC): Final results of a randomised phase III trial

David F. Heigener, L Freitag, C. Eschbach et al. · Journal of Clinical Oncology · 2008 · 29 citations

Cancer Management, Pharmacotherapy, Standard Arm +18

Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM)

Martin Reck, Maciej Krzakowski, Jacek Jassem et al. · Journal of Clinical Oncology · 2009 · 19 citations

Cancer Management, Pathology, Tumor Biology +16